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Background: MicroRNA (miRNA) expression is known to be deregulated in cervical carcinomas. However, no data
is available about the miRNA expression pattern for the minimal deviation adenocarcinoma (MDA) of uterine cervix.
We sought to detect deregulated miRNAs in MDA in an attempt to find the most dependable miRNA or their
combinations to understand their tumorigenesis pathway and to identify diagnostic or prognostic biomarkers. We
also investigated the association between those miRNAs and their target genes, especially Notch1 and Notch2.
Methods: We evaluated miRNA expression profiles via miRNA microarray and validated them using.real-time PCR
assays with 24 formalin-fixed, paraffin-embedded tissue blocks of MDA and 11 normal proliferative endocervical
tissues as control. Expression for Notch1 and 2 was assessed by immunohistochemistry.
Results: MiRNA-135a-3p, 192-5p, 194-5p, and 494 were up-regulated, whereas miR-34b-5p, 204-5p, 299-5p, 424-5p,
and 136-3p were down-regulated in MDA compared with normal proliferative endocervical tissues (all P <0.05).
Considering the second-order Akaike Information Criterion consisting of likelihood ratio and number of parameters,
miR-34b-5p showed the best discrimination power among the nine candidate miRNAs. A combined panel of
miR-34b-5p and 194-5p was the best fit model to discriminate between MDA and control, revealing 100% sensitivity
and specificity. Notch1 and Notch2, respective target genes of miR-34b-5p and miR-204-5p, were more frequently
expressed in MDA than in control (63% vs. 18%; 52% vs. 18%, respectively, P <0.05). MiR-34b-5p expression level
was higher in Notch1-negative samples compared with Notch1-positive ones (P <0.05). Down-regulated miR-494
was associated with poor patient survival (P =0.036).
Conclusions: MDA showed distinctive expression profiles of miRNAs, Notch1, and Notch2 from normal proliferative
endocervical tissues. In particular, miR-34b-5p and 194-5p might be used as diagnostic biomarkers and miR-494 as a
prognostic predictor for MDA. The miR-34b-5p/Notch1 pathway as well as Notch2 might be important oncogenic
contributors to MDA.
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Table 1 Clinicopathological characteristics of patients
with minimal deviation adenocarcinoma (n =24)
Characteristics No. (%)
Age (median, range; yrs) 46 (30–59)
Tumor size
≤4 cm 15 (62.5)
>4 cm 9 (37.5)
Stage
Low (I/II) 21 (87.5)







Overall survival (range; months) 4–135
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Minimal deviation adenocarcinoma (MDA), also known
as adenoma malignum, is an extremely well-differentiated
variant of cervical adenocarcinoma in which most of
the cells lack the cytological features of malignancy [1].
Although MDA is an uncommon tumor and accounts
for only 1 to 3% of all cervical adenocarcinomas [1], it
deserves scrutiny because many non-neoplastic endocervi-
cal glandular lesions encountered in daily practice should
be differentiated from it. Because it is very difficult to
diagnose preoperatively if the proliferative endocervical
glandular lesion is definitely benign or malignant, espe-
cially in punch biopsy specimens [2], it would be crucial
to combine ancillary molecular or immunohistochemical
biomarkers with morphologic characteristics in order to
improve diagnostic accuracy. In 1998, a Japanese group
initially demonstrated that MDA showed immunoreac-
tivity with HIK1083 [3], and ever since this antibody has
been considered a promising tool for establishing the
diagnosis of MDA. However, its usefulness has been in
dispute because its immunoreactivity has also been
demonstrated in several proliferative endocervical glan-
dular lesions exhibiting gastric differentiation, including
lobular endocervical glandular hyperplasia (LEGH) or
gastric-type adenocarcinoma in situ (AIS), as well as in
MDA [4,5].
Whereas most cases of cervical carcinomas are known
to be associated with high-risk human papillomavirus in-
fection, MDA is usually found to be negative for human
papillomavirus [1,6,7]. Although some authors suggested
that MDA could be derived from LEGH and morpho-
logically usual-type AIS showing gastric immunopheno-
type [1,4], further studies would be needed to draw this
conclusion. Previous reports for prognosis of MDA have
not provided uniform data. Several investigators reported
poor prognosis [8-10], whereas some found a relatively
favorable prognosis similar to that for other well-
differentiated cervical adenocarcinomas [11-13]. Therefore,
difficulty in morphologic diagnosis, uncertain pathogenesis,
and variable clinical outcome data prevent clinicians
from guiding patient clinical management and treatment
effectively.
MicroRNAs (miRNAs) are small non-coding RNAs
that have been implicated in tumor development [14,15].
They regulate target gene expression either by mRNA
degradation or by translation repression [14-18]. In
general, each miRNA can regulate up to hundreds of
target genes [14-18]. During tumor development, aberrant
expression of miRNAs can either inactivate tumor sup-
pressor genes or activate oncogenes, thereby promoting
tumor formation [14-16,18,19]. Because expression of
miRNAs is tissue-specific [14,15], detectable in blood [20],
and correlates with clinical cancer behaviors [21], miRNAs
are potentially valuable biomarkers.Until recently, several studies have identified either
up-regulated or down-regulated miRNAs in cervical
cancers using the global profiling method [22-29] or
the candidate miRNA approach [30]. However, most
studies determined miRNA expression profiles in
cervical squamous cell carcinomas [22-30], although
a few adenocarcinoma cases were included in the
cervical cancer category. There has been no report
about the miRNA expression profiles on an inde-
pendent set of cervical adenocarcinomas, in particu-
lar, MDA.
Characterization of the complex relationship between
deregulated miRNAs and their target genes in MDA
may not only help to define some of the molecular path-
ways that drive carcinogenesis, but those biomarkers
would also help to improve discrimination between
MDA and other glandular lesions and be of considerable
importance for the prediction of prognosis.
Methods
Tissue samples and patients
A total of 24 archived formalin-fixed paraffin-embedded
(FFPE) tissue blocks of MDA, excluding cases associated
with Peutz-Jeghers syndrome, were obtained from the
pathology department of 13 hospitals in Korea. A central
review with hematoxylin-eosin-stained slides was under-
taken by at least 10 pathologists from the Gynecological
Pathology Study Group of the Korean Society of Pathol-
ogists. Of 24 carcinomas, 11 cases were in stage Ib, 8 in
stage II, 1 in stage III, and 2 in stage IV, according to the
International Federation of Gynecology and Obstetrics
standards. A total of 11 cases of normal proliferative
endocervical tissue (NE) were obtained from the patients
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such as adenomyosis or leiomyoma. For minimal deviation
adenocarcinoma, we selected only the mucinous variant of
MDA since they are the main targets and discrimination
from various non-neoplastic proliferative endocervical
lesions as well as normal endocervix must be made.
Only tissue blocks with more than 70% carcinoma con-
tent were used for this study. The clinicopathological
characteristics of the patients are summarized in Table 1.
This study protocol was approved by the Institutional
Review Board of Bucheon St. Mary’s Hospital from the
Catholic University of Korea.
RNA extraction
Total RNA was extracted from FFPE tissues using an
miRNeasy FFPE kit (Qiagen, Hilden, Germany) followingFigure 1 Unsupervised hierarchical clustering analysis based on miRN
(MDA) (C1–C8) and 8 normal proliferative endocervical tissues (NE) (N1–N8
miRNAs (green) in MDA compared to NE.the manufacturer’s instructions. RNA concentration and
purity were assessed using a UV spectrophotometer.
MicroRNA expression profiling assay
For the selection of the candidate miRNAs, we evalu-
ated miRNA expression profiles of 8 MDA and 8 NE
samples which were randomly selected. The miRNA
Microarray System with miRNA Complete Labeling
and Hybridization kit (SurePrint G3 Human miRNA
Microarray, Release 18.0, 8×60K, Agilent Technologies,
Santa Clara, CA, USA) containing 1,887 human miRNA
oligonucleotide probes was used according to the manu-
facturer’s recommended protocol. The Agilent micro-
RNA Spike-In kit was used for in-process control to
measure labeling and hybridization efficiency. Arrays were
scanned on an Agilent Technologies G4900DA SureScanA array data. Array data from 8 minimal deviation adenocarcinomas
) shows 47 overexpressed miRNAs (red) and 49 underexpressed
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scanning were performed by Macrogen Inc. (Seoul,
Korea).
Reverse transcription and quantitative real-time PCR
Reverse transcription and quantitative real-time PCR
(qRT-PCR) were performed for the validation of the
selected miRNAs using the MicroRNA TaqMan® Re-
verse Transcription Kit and the TaqMan MicroRNA
Assays in triplicate (Applied Biosystems, Foster City,
CA, USA). U6 small nuclear 2 (RNU6b) was used to
normalize input total small RNA. Absolute quantifi-
cation for each miRNA as well as RNU6b was per-
formed using a standard curve generated by serial
dilution of reverse-transcribed total RNA extracted
from VK2 cells, and expression of each miRNA was
presented as the ratio between miRNA and RNU6b
(RQ).Figure 2 Validation of the differentially-expressed miRNAs from the m
miRNA in a validation set composed of normal proliferative endocervical ti
cervix is shown by an individual scatter plot.Immunohistochemical analysis
Immunohistochemistry for Notch1 (Cell Signaling Tech-
nology, #3608, Danvers, MA, USA; dilution 1:100) and
Notch2 (sc-5545, Santa Cruz Biotechnology, Santa Cruz,
CA, USA; dilution 1:100) were performed using standard
staining procedures as described previously [31]. All cases
were reviewed and interpreted without knowledge of
other laboratory or clinical results. Immunohistochemical
reactions were categorized simply as positive or negative
because of the small number of tissue samples.
Raw data preparation and statistical analysis
Raw data from the microarray analysis were extracted using
the Agilent Feature Extraction Software (v11.0.1.1). The
array data were filtered by “gIsGeneDetected” =1 in all sam-
ples (1: detected). The selected “miRNAgtotalGeneSignal”
value was logarithmically transformed and normalized by
the quantile method. A comparative analysis between theicroarray data with real-time quantitative PCR. Expression of each
ssues (NE) and minimal deviation adenocarcinoma (MDA) of uterine
Table 2 Univariate and multivariate logistic regression
analysis result and AICc values for differentiating MDA
from NE
ln miRNAs OR 95 % CI P value AICc value
miR-34b-5p 0.012 0.002–0.358 <0.001 10.069
miR-135a-3p 3.938 1.348–11.510 0.012 36.902
miR-136-3p 0.144 0.032–0.046 0.011 38.194
miR-192-5p 31.808 2.912–347.453 0.005 20.098
miR-194-5p 7.921 1.933–32.459 0.004 31.019
miR-204-5p 0.133 0.031–0.561 0.006 30.576
miR-299-5p 0.006 0.000 – 0.116 0.002 16.953
miR-424-5p 0.011 0.000–0.411 0.015 15.014
miR-494 26.278 1.861–370. 966 0.016 25.869
Best fit
ln miR-34b-5p 0.149 0.008–0.453 <0.001
ln miR-194-5p 4.035 1.150–50.958 0.032
constant 0.017 0.000–0.662 0.027 8.190
MDA, Minimal deviation adenocarcinoma; NE, Normal proliferative
endocervical tissue; OR, Odds ratio; CI, Confidence interval; AICc, Second-order
Akaike Information Criterion.
Table 3 Capabilities of the ln miRNAs to discriminate
MDA from NE
ln miRNAs AUC (SE) Sensitivity % Specificity % P value
miR-34b-5p 1.000 (0.000) 100.0 100.0 0.000
miR-135a-3p 0.833 (0.078) 70.8 81.8 0.002
miR-136-3p 0.814 (0.072) 70.8 90.9 0.003
miR-192-5p 0.955 (0.039) 91.7 100.0 0.000
miR-194-5p 0.943 (0.043) 95.8 81.8 0.000
miR-204-5p 0.886 (0.060) 80.3 90.9 0.000
miR-299-5p 0.981 (0.013) 91.6 90.9 0.000
miR-424-5p 0.981 (0.021) 100.0 90.9 0.000
miR-494 0.909 (0.057) 91.7 90.9 0.000
2 miRNAs* 1.000 (0.000) 100.0 100.0 0.000
MDA, Minimal deviation adenocarcinoma; NE, Normal proliferative
endocervical tissue; AUC, Area under receiver-operating characteristics curve;
SE, Standard error.
*Model is constructed using Firth’s bias reduced logistic regression analysis.
All P <0.05.
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and an independent t-test. The false discovery rate was con-
trolled by adjusting P value using the Benjamini-Hochberg
algorithm. Hierarchical cluster analysis was performed
using complete linkage and Euclidean distance as a
measure of similarity.
The RQ values in qRT-PCR data were logarithmically
transformed due to highly skewed distribution of RQ
levels. The Mann–Whitney test and χ2 test were used to
compare the miRNA, Notch1, and Notch2 expression
between MDA and NE specimens. To determine the
correlation between miRNAs and pathological diagnoses,
we conducted a Firth’s bias reduced logistic regression
analysis [32] to reduce the bias due to “separation” and
significant multicolinearties between miRNAs. The best-
fit model was determined by the second order Akaike
Information Criterion (AICc). The receiver-operating
characteristic (ROC) curves were constructed; the sensi-
tivity and specificity at each cut-off value and area under
the ROC curve (AUC) were estimated. The correlation
between two most down-regulated miRNAs and their
target genes, Notch1 and Notch2, and the correlation
between miRNA or Notch expressions and clinicopatho-
logic parameters were evaluated with the Mann–Whitney
test. Survival curves were produced via the Kaplan-Meier
method and the resulting curves were compared using the
log-rank test. P values <0.05 were considered statistically
significant. Due to a small number of cases, we could
not derive strong correlation between miRNAs, Notch
1, Notch 2, and clinicopathologic parameters. Statistical
analysis was performed using R statistical language v.
2.15.0 and SPSS 17.0.
Results
Results of microRNA microarray analysis
We examined the expression levels of miRNAs in MDA
(n =8) and NE (n =8), for a total of 16 independent
samples. Using unsupervised hierarchical clustering
analysis without any information on the identity of the
samples, a tree was generated that represented a clear
separation of MDA from NE (Figure 1). Among 1,887
miRNAs analyzed, there was a significant difference in
the expression level of 96 miRNAs (47 up-regulated and
49 down-regulated) with more than a three-fold change
between MDA and NE. Among these, the most signifi-
cantly overexpressed miRNAs in MDA were miR-494,
135a-3p, 513a-5p, 194-5p, 192-5p, and 188-5p, whereas
the most significantly down-regulated miRNAs were miR-
34b-5p, 204-5p, 299-5p, 424-5p, and 136-3p.
Results of validation study on reverse transcription and
quantitative real-time PCR
To validate the data from the miRNA microarray, we
used qRT-PCR to analyze the expression levels of the sixup-regulated and five down-regulated candidate miRNAs,
using a set of MDA (n =24) and NE (n =11), including the
samples used for microarray analysis. Expression levels of
four miRNAs (miR-494, 135a-3p, 194-5p, and 192-5p)
were significantly higher and those of five miRNAs
(miR-34b-5p, 204-5p, 299-5p, 424-5p, and 136-3p) were
significantly lower in MDA when compared with NE
(P <0.05 for both; Figure 2). Through a validation
study, we found that miR-513a-5p and miR-188-5p were
not significantly up-regulated in MDA compared to con-
trol, unlike the microarray data. Thus, we discarded those
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were confirmed by real-time PCR.
MicroRNAs as biomarkers for detecting minimal deviation
adenocarcinoma
The individual miRNAs exhibited a significant correlation
with MDA in univariate logistic regression analysis with
AICc values ranging from 10.069 to 38.194 (all P <0.05).
The best single miRNA to discriminate MDA from NE
was miR-34b-5p with an AICc value of 10.069 (Table 2).
To discriminate MDA from NE samples, the compositeFigure 3 Immunohistochemical staining of Notch1 and Notch2 in min
correlation with miRNAs. (A) Notch1 is predominantly localized at the ap
tumor cells. High magnification view (inset, ×400). Differential expression o
endocervical tissue (NE). Expression levels of (E) miR-34b-5p and (F) miR-20panel of two miRNAs (miR-34b-5p and 194-5p) was
determined to be the best fitting model, using Firth’s
bias reduced multivariate logistic regression analysis.
The following regression equation was built: Logit
(P) = −4.068 – 1.900* (ln miR-34b-5p) +1.396* (ln
miR-194-5p). The odds ratios of ln miR-34b-5p and
194-5p were 0.149 and 4.035, respectively, and this
model exhibited an AICc value of 8.190, which is lower
than that of any single miRNA (Table 2).
The individual miRNAs exhibited AUC values of 0.814
to 1.000 in distinguishing MDA from NE, revealing 70.8imal deviation adenocarcinoma (MDA) of uterine cervix and their
ical membranes and (B) Notch2 is expressed in the cytoplasm of the
f (C) Notch1 and (D) Notch2 in MDA compared to normal proliferative
4-5p according to Notch1 and Notch2 status, respectively.
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Table 3). The best fitting model consisting of miR-34b-5p
and 194-5p produced an AUC value of 1.000, 100% sensi-
tivity, and 100% specificity (P <0.01) (Table 3).
Selected microRNAs and computational analysis for their
predicted target genes
We identified the predicted target genes via web-based
computational approaches (miRDB; http://mirdb.org, ver
4.0, miRBase rel.18.0). We discovered that Notch1 and
Notch2 were the target genes of the most down-regulated
miRNAs, miR-34b-5p and miR-204-5p, respectively.
Notch1 and Notch2 status and association with microRNA
expression
Notch1 and Notch2 expressions were determined by im-
munohistochemical analysis (Figure 3A, B) in the same
set of MDA (n =24) and NE (n =11) used for qRT-PCR.
Notch1 was detected in 11 of 24 MDA (63%) and 2 of
11 NE (18%) samples, whereas Notch2 was detected in
13 of 24 MDA (52%) and 2 of 11 NE (18%) samples. The
percentages of positive Notch1 and Notch2 samples
were significantly higher in MDA compared with NE
samples (63% vs. 18%, P =0.015 and 52% vs. 18%, P =0.046,
respectively; Figure 3C, D). Expression of miR-34b-5p
was significantly up-regulated in Notch1-negative sam-
ples compared with Notch1-positive samples (P =0.008;
Figure 3E). However, miR-204-5p did not show a sig-
nificant correlation with the Notch2 expression pattern
(P =0.894; Figure 3F).
Association with clinicopathological parameters and
survival
Down-regulation of miR-494 was associated with poor
patient survival (P =0.036; Figure 4). We found no signifi-
cant association between miRNA expression and tumor
size, clinical stage, lymph node, or distant metastasis, nor
between Notch expression and various clinicopathological
parameters (see Additional file 1).Figure 4 Kaplan-Meier survival curve and log-rank test for
miR-494 level. The survival rate of patients with down-regulated
miR-494 levels was significantly lower than that of patients with
up-regulated miR-494 levels (log-rank test P =0.036).Discussion
Preoperative differential diagnosis of MDA from other
proliferative glandular lesions, such as endocervical tunnel
clusters [1], deeply situated nabothian cysts [1], endocervi-
cosis of the cervical wall [1], mesonephric hyperplasia [1],
LEGH [2], and AIS [2], is critical for appropriate thera-
peutic management. Nonetheless, according to a previous
report [2], the interobserver agreement rate for MDA
showed just a slight level of consistency (k-value =0.115).
Recently, several studies have noted associations between
microRNA expression and cervical carcinomas [22-30].
MiRNAs reported in the previous studies [22-30] to be as-
sociated with cervical carcinomas included the following:
miR-21, 143, 21, 145, 218, 29a, 155, 16, 146a, 20a, 126,
127, 424, 17-5p, 203, 20, 15b, 106a, 148a, 224, 10b, 450,
199a, 20b, 125b, 15a, 93, 182, 185, and 34a. However,
those studies revealed quite different miRNA expression
profiling patterns from ours because most studies have fo-
cused on cervical squamous cell carcinomas. These find-
ings are explained by the previous reports that have
suggested tissue-specific miRNA expression patterns with
different sets of miRNAs up- or down-regulated in tumors
of different cellular origin [33-35].
In the present study, using miRNA microarray and
qRT-PCR on 24 MDA samples, we detected nine miRNAs
which were differently expressed between MDA and NE.
They exhibited relatively good discrimination ability and,
in particular, single miR-34b-5p testing could discriminate
MDA from NE with 100% sensitivity and specificity. We
also constructed the best fitting model consisting of
miR-34b-5p and 194-5p based on AICc values, and it
also showed 100% sensitivity and specificity. Considering
the high sensitivity and specificity above 99%, they might
be used as supplementary diagnostic biomarkers in patho-
logically complicated cases with ambiguous morphological
features or with only small amounts of superficial glandu-
lar lesions upon limited sampling.
Four Notch genes have been described in mammals,
Notch1, Notch2, Notch3, and Notch4 [31,36,37]. They
encode type I transmembrane proteins with extracellular
domains containing epidermal growth factor-like repeats
that regulate cell proliferation and differentiation in
various tissues [31,36,37]. In cervical cancer, upregula-
tion of Notch1 [37-39] and Notch2 [39] was associated
with in-situ or invasive squamous cell carcinoma and
adenocarcinoma, and it is thought that abnormal Notch
signaling can promote the development of cervical can-
cer [40]. In the present study, Notch1 and Notch2
seemed to play an oncogenic role because both of them
were significantly up-regulated in MDA compared to
normal control. Interestingly, although we observed that
Notch1 expression was dependent on the miR-34b-5p
expression level, Notch2 expression did not seem to be
dependent on the miR-204-5p expression level, thereby
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involved in the Notch2 expression process in the MDA
carcinogenesis pathway. In particular, considering that
miR-34b-5p and Notch1 showed the most distinctive
expression pattern between MDA and NE, we can specu-
late that down-regulation of miR-34b-5p and the resulting
overexpression of the Notch1 gene (miR-34b-5p/Notch1
pathway) might comprise one of the important oncogenic
pathways of MDA. However, Notch2 is positive in 52% of
MDAs compared to 18% of normal control samples, and
this finding alone may be sufficient to suspect that Notch2
could also play a role in carcinogenesis of MDA, although
maybe not triggered by miR-204-5p.
To date, several miRNAs, including miR-375 [41], 127
[24], 9 [42], 200a [42,43], 93 [43], 497 [44], and 224 [45],
have been reported to be associated with metastasis,
progression, or survival of cervical cancer, although most
of the cervical tumors in those studies were also squa-
mous cell type. In this study, down-regulation of miR-494
was associated with poor patient survival, suggesting its
possible role as a prognostic marker.
Limitations to our study need to be mentioned. First,
even though we performed a multicenter study, there was
still only a small number of cases due to the low incidence
of MDA. Thus, we could not afford another validation
study for our diagnostic or prognostic biomarkers with a
test set, and future studies with larger sample size, notably
including controversial cases, will have to be performed.
Second, a possible precursor lesion, like LEGH or gastric
type-AIS, which could strengthen our hypothesis was not
included in this study. Third, more experiments, such as
transfection of miR-34b-5p and cell viability tests, are still
warranted to reveal the exact role of the miR-34b-5p/
Notch1 pathway during MDA carcinogenesis.
Conclusions
MDA showed distinctive expression profiles of miRNAs,
Notch1, and Notch2 from NE. In particular, miR-34b-5p
and 194-5p might be used as diagnostic biomarkers and
miR-494 as a prognostic predictor for MDA. The miR-34b-
5p/Notch1 pathway as well as Notch2 might be important
oncogenic contributors to MDA.
Additional file
Additional file 1: Correlations between miRNA or Notch
expressions and clinicopathological parameters.
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